Seeking Alpha

Steve Rosenman's  Instablog

Steve Rosenman
Send Message
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of... More
  • Kudos To Adam Feurstein, For Once... 25 comments
    May 29, 2013 8:51 AM | about stocks: AMRN, GSK, AZN

    For once, AF steps up to correct a near-criminal statement by Summer Street (not AF), a known-short seller of Amarin shares. Hopefully, he can keep up reporting accurate, useful information.

    I have said for some time, FDA will approve the Anchor indication in December, and they will. GSK and now AZN have no answer to Anchor, and that's a big deal. Neither one of their therapies effectively reduce TG levels as pure EPA in the 200-500 population. This is proven by no dose dependent effect by Epanova (huge trouble) and the fact that for more than 7 years GSK has never expanded Lovaza--because they know it doesn't work in Anchor.

    If AF wants to take the stance that he does not believe they will get approval in December, that's fine and if he states his position, no issue respecting and disagreeing with it. But, Summer Street will now be getting serious SEC inquiries and I am already hearing quite serious trouble will be brewing as their position in Amarin has been under investigation.

    Stocks: AMRN, GSK, AZN
Back To Steve Rosenman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (25)
Track new comments
  • I respectfully disagree on kudos to Adam part. Adam Feuerstein has been involved in slandering and miss reporting key facts regarding AMRN and this was not the first time. He likes to hide under comments such as "a source" or whatever. He coordinates attacks with writers that he has been linked with for years. All you have to do is google Adam Feuerstein and any articles writers name that has bashed Amrn and you will see them bashing the same stocks and re-tweeting each other. Adam knows what he is doing and its not a coincidence. I and many others sent serious complaints to AMRN first thing in the morning and I am glad finally this nonsense is starting to get exposed. AMRN must press charges and not let these idiots get awway with what they are doing.
    29 May 2013, 09:46 AM Reply Like
  • Author’s reply » It was a joke.
    29 May 2013, 10:16 AM Reply Like
  • Adam just tweeted this


    "Adam Feuerstein ‏@adamfeuerstein 20m
    SummerStreet on $AMRN: "We stand by yesterday’s comments and state our story is accurate.""


    AMRN must take action......
    29 May 2013, 10:19 AM Reply Like
  • So this is from today's SA's market currents news (if AMRN is in your portfolio here, you probably got mail alert about this too):


    9:58 AM AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct commercial advantage" ( ) over Amarin (AMRN +0.3%), says Decision Resources' Paramjit Narang. Omthera's Epanova drug "offers higher and more constant bioavailability, and arguably better efficacy" in lowering triglyceride than Amarin's Vascepa, and it "lacks the gastrointestinal side effects of the market incumbent Lovaza," which is sold by GSK (GSK -2%). Narang reckons Epanova's annual sales could peak at $1B.
    29 May 2013, 10:38 AM Reply Like
  • What a ridiculous pump job by Narang, it's laughable. Hey brainiac - why no mention of IP or patents for OMTH's Lovaza clone? Oh, that's right - THEY DON'T HAVE ANY! Not a single patent. Oopsie! Generic competition before they even file their NDA?
    29 May 2013, 01:14 PM Reply Like
  • Author’s reply » That's from an analyst who doesn't no jack about the science. The bioavailability play is moot, since the drug shows no dose dependent benefits. MDs wont prescribe it due to its side effects.
    29 May 2013, 11:01 AM Reply Like
  • Yeah, it does sound pretty clear that the latest comments are spoken out of their position. A company gets bought out by another company and all they focus about is a 3rd company.


    Makes you think though, could Amrain rise with all them naysayers around.. Steve could you get Icahn\Soros to take a small position in AMRN?
    29 May 2013, 11:16 AM Reply Like
  • Ok got it. lol..That guy has 0 credibility. He taunts shareholders. What kind of person does that?
    29 May 2013, 11:08 AM Reply Like
  • also, someone should ask mgt at omthera why they only ran a six week trial for their version of Anchor versus a 12 week trial for their version of Marine. (Anchor and Marine were 12 week trials). Maybe they learned that the GI issues with their drug get worse the longer you take it. Only so long till you have to run to the outhouse...
    29 May 2013, 11:14 AM Reply Like
  • Author’s reply » I am very well versed on what OMTH mg't was trying to do during investor roadshows, they were getting zero traction from private equity, so they went public. Their stuff has limits and will not get beyond the Marine indication, if they can even compete on that...
    29 May 2013, 11:29 AM Reply Like
  • Author’s reply » Epanova is the free fatty acid form of Lovaza. The main negative is that it did not show dose dependent benefit, meaning you cannot easily expand the indication without going back to the drawing board.


    They will never get anchor results
    29 May 2013, 01:30 PM Reply Like
  • Steve,
    Please include in your article comparisons of bioavailability results please. Also not many aware but big brother will start looking over the shoulder on any studies done in treating lipid modifying agents. Corporations better be on their toes because it looks as if BB data doesn't match what Corporate gets, some heads could role.



    I've heard from some very reliable sources that Epanova is believed by several major institutions that it will become First Class Drug of choice for hypertrigs. One of the firms is currently our advocate. My research apparently does not match their research. Only advantages I currently see is dosage schedule, size of capsule and bioavailability superior to Lovaza (all only addressing Marine indication). Unless these instos are privy to bio results not yet published, I struggle with their logic.


    Also, if this is factual, why was their IPO a dismal failure and was only supported above 7 by institutions buoying up the price in agreement with their contract??


    Your articles are excellent. I look forward to seeing the facts in the near future. P.S. John Thero just exercised 11,000 options and converted to shares which he kept. My understanding is that there is a very small window of time each quarter for the insiders to participate in the public markets. What this form 4 means is anyone's guess however.


    Keep up the great work!
    29 May 2013, 05:06 PM Reply Like
  • Wonder why AHRQ left in combos of statins + niacin? The AIM-HIGH study using Niaspan + Simvastatin was halted after only 18 months because no benefits were found, and incidence of stroke actually went UP? Niacin has not been shown to do anything good in actual outcomes. Weird, to say the least....
    29 May 2013, 05:46 PM Reply Like
  • Good info,Steve.
    29 May 2013, 04:24 PM Reply Like
  • remember, GSK was fined heavily for off-label use of Lovaza, they tried to market to the Anchor class, and got a big fine, I think 200-250m dollars or something like that. That's worth over a buck in AMRN shares just what got fined to GSK
    29 May 2013, 04:24 PM Reply Like
  • Don't know how much GSK got fined spedifically for the Lovaza marketing gaff, but the TOTAL amount they had to pay for the combined lawsuites was around $3.2 BILLION, largest on record IIRC.
    29 May 2013, 05:48 PM Reply Like
  • and then he tweeted saying that ... Still thinks ANCHOR will be rejected
    29 May 2013, 04:24 PM Reply Like
  • Not positive but appears we got our very first Euro patent today

    29 May 2013, 11:04 PM Reply Like
  • Well, Steve
    It was a wonderful opportunity to add more to 2015 jan 10 options.
    golden opportunity and amarin will succeed in coming months. Appreciate your hard work on amarin.
    30 May 2013, 09:31 AM Reply Like
  • up 30% on latest round of calls I bought..Over 40,000 share position now with calls (all leaps)


    My take is that today Irish is giving Irish a hand before a realistic offer is made not by Elan but by someone else. Only time will tell. You cant make a 25 offer for a $7 stock but you can for a $10-$12 stock.
    30 May 2013, 11:18 AM Reply Like
  • But you can make a 17.50 offer plus 4 for NCE and 7.50 for anchor approval. This type of deal is about to happen. I do think it is PFE.
    30 May 2013, 07:10 PM Reply Like
  • Steve


    What do you think of the royalty deal as a strategic approach - if ELN warchests up the company to hire a big salesforce for Anchor and then reaps a royalty. Mgt has laid the groundwork w the Marine lauch already and would have the funds to get the word out. Does this make sense? Feels like the trade off would be stock price that could over the long run go to the moon balanced against increased short term launch risk...
    30 May 2013, 04:58 PM Reply Like
  • Author’s reply » Honestly, PFE is the best, followed by AZN, then GSK, Merck, Elan and finally Teva. Why Teva, just b/c they would be able to control both generic and brand plays which could be interesting...
    31 May 2013, 10:09 AM Reply Like
  • Why can't we sell at $15 and get on with it- I just want my initial investment back. I doubt that Steve really believes this will get to. $30. But who knows- stranger things have happened!
    5 Jun 2013, 10:37 AM Reply Like
  • New medscape article mentioning Vascepa. Link below

    6 Jun 2013, 12:07 AM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.